VERAXA Biotech Advances Lead BiTAC® T-Cell Engager Program With Cell Line Development Partnership

VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has begun cell line development for its lead BiTAC® T-cell engager ("BiTAC®-TCE") program, marking another step in preparing the company’s most advanced oncology candidate for future clinical development. The company has selected ATUM, a U.S.-based contract research organization specializing in bioengineering and cell line development, to generate stable clonal cell lines using its proprietary Leap-In Transposase® technology. According to VERAXA, the collaboration is intended to support manufacturing, analytical development and nonclinical studies required before clinical testing.

This partnership represents an important development milestone for VERAXA as it advances its lead BiTAC® T-cell engager program toward IND/CTA-enabling studies. The BiTAC® platform is designed to improve the selectivity of T-cell engagers, potentially reducing toxicity associated with conventional approaches. The company recently expanded its research facilities in Heidelberg, Germany, increasing laboratory capacity as multiple oncology programs move toward clinical development.

The cell line development process is a critical step in biopharmaceutical manufacturing, ensuring that the therapeutic protein can be produced consistently and at scale. By leveraging ATUM's Leap-In Transposase® technology, VERAXA aims to accelerate the timeline to clinical trials. The company has not disclosed specific timelines for the IND filing but emphasized that this partnership is a key enabler for future clinical development.

VERAXA’s focus on improving T-cell engager selectivity addresses a significant challenge in cancer immunotherapy: toxicity. Many T-cell engagers can cause severe adverse effects due to off-target activation. The BiTAC® platform aims to mitigate this risk, potentially offering a safer treatment option for patients. The company’s lead program targets a yet-undisclosed tumor antigen, and preclinical data have shown promising efficacy and safety profiles.

The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA. For more information on VERAXA Biotech, including full terms of use and disclaimers, please visit the InvestorBrandNetwork website at http://IBN.fm/Disclaimer.

Forward-looking statements in this article involve risks and uncertainties that may cause actual results to differ materially. These include factors beyond management's control, as detailed in the company's filings with the SEC. Undue reliance should not be placed on forward-looking statements, and the company undertakes no duty to update this information unless required by law.